Columvi

News

FDA starts swift review of Regeneron’s CD20 bispecific

The FDA has started a priority review of Regeneron’s CD20xCD3 bispecific antibody odronextamab, seeking a broader label than other drugs in the class.

News

AbbVie nears EU nod for DLBCL drug epcoritamab

AbbVie and Genmab’s would-be blockbuster epcoritamab has been recommended for conditional approval in the EU as a treatment for diffuse large B-cell lymphoma (DLBCL), an a

News

Chasing AbbVie, Roche gets FDA OK for DLBCL bispecific

Roche has claimed FDA approval for its CD20xCD3 bispecific antibody Columvi as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), setting up an

FDA starts swift review of Regeneron’s CD20 bispecific

AbbVie nears EU nod for DLBCL drug epcoritamab

Chasing AbbVie, Roche gets FDA OK for DLBCL bispecific

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Editor's Picks